Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $22.99 Million Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 9.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 429,392 shares of the company's stock after selling 42,344 shares during the period. Janux Therapeutics comprises about 2.8% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s portfolio, making the stock its 17th biggest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.82% of Janux Therapeutics worth $22,990,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares in the last quarter. Avanza Fonder AB purchased a new position in Janux Therapeutics in the fourth quarter worth $139,000. Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at $159,000. Tower Research Capital LLC TRC raised its position in Janux Therapeutics by 878.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after acquiring an additional 3,436 shares during the period. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Janux Therapeutics in the fourth quarter valued at $221,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Price Performance

Shares of JANX opened at $24.17 on Tuesday. The firm has a market capitalization of $1.43 billion, a P/E ratio of -20.66 and a beta of 3.24. The business has a fifty day moving average of $28.50 and a 200 day moving average of $40.33. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Wedbush reaffirmed an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Finally, Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $95.25.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $30.00, for a total value of $100,020.00. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,464,170. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the acquisition, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 10,001 shares of company stock worth $313,964 over the last 90 days. Corporate insiders own 8.10% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.